These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17545531)

  • 1. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
    Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
    J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
    Casali C; Cucca M; Rossi G; Barbieri F; Iacuzio L; Bagni B; Uliano M
    Lung Cancer; 2010 Aug; 69(2):187-93. PubMed ID: 19942313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
    Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ
    Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with true pathologic stage I non-small cell lung cancer.
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2009 Sep; 88(3):917-22; discussion 922-3. PubMed ID: 19699920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
    Lee PC; Port JL; Korst RJ; Liss Y; Meherally DN; Altorki NK
    Ann Thorac Surg; 2007 Jul; 84(1):177-81. PubMed ID: 17588407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
    Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
    Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx.
    Kim SY; Roh JL; Kim MR; Kim JS; Choi SH; Nam SY; Lee SW; Kim SB
    J Nucl Med; 2007 May; 48(5):752-7. PubMed ID: 17475963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis.
    Vesselle H; Turcotte E; Wiens L; Schmidt R; Takasugi JE; Lalani T; Vallières E; Wood DE
    Clin Cancer Res; 2004 Jul; 10(14):4709-16. PubMed ID: 15269143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer.
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Jul; 84(1):182-8; discussion 189-90. PubMed ID: 17588408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
    Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
    Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
    Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
    Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.